• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is AbCellera Biologics (ABCL) Undervalued On Its ABCL635 Phase 2 Data Presentation?

    Simply Wall St·09/26/2026 21:18:17
    Listen to the news

    AbCellera Biologics (NasdaqGS:ABCL) just flagged a key clinical moment, with Phase 2 data for its menopause-focused antibody ABCL635 set for oral presentation at the International Menopause Society’s World Congress.

    That clinical spotlight lands after a sharp run in the shares, with AbCellera Biologics delivering a 90 day share price return of 72.09% and a year to date share price return of 270.26%. The 1 year total shareholder return of 167.93% points to momentum that has been building rather than fading over a longer stretch.

    Spot emerging momentum stories around AbCellera Biologics by scanning our curated set of 16 high quality undiscovered gems. This collection highlights companies that pair early-stage pipelines with balance sheets built to fund long development cycles.

    Bulls see AbCellera Biologics as a high conviction pipeline platform that is now getting credit, while bears see an overheated biotech story. Which view does the current valuation actually support?

    Most Popular Narrative: 26% Undervalued

    On the most followed view, AbCellera Biologics trades below an estimated fair value of $17.13, compared with a last close of $12.70. This view puts a lot of weight on how the menopause and autoimmune programs mature from here.

    The initiation of Phase I clinical trials for ABCL635 and ABCL575, with differentiation factors such as a unique dosing regimen and a reported improved safety profile for ABCL635, is expected to position the company to capture a market opportunity in an underserved area, potentially boosting future revenue.

    AbCellera's transition from a platform company to a clinical-stage biotech, along with the development of internal programs, suggests a shift towards generating revenue from downstream milestone fees and royalty payments as new molecules are expected to reach the clinic.

    See why 58 investors see AbCellera Biologics as 26% undervalued.

    Result: Fair Value of $17.13 (UNDERVALUED)

    Still, the widening net loss and heavy R&D spend, alongside dependence on ABCL635 delivering in later trials, could quickly challenge this 26% undervalued narrative.

    Find out about the key risks to this AbCellera Biologics narrative.

    Next Steps

    If the mixed tone on AbCellera Biologics has you torn, consider acting quickly and reviewing the numbers yourself so you are not relying on headlines alone. To weigh the potential upside alongside the concern points in one place, start with the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond AbCellera Biologics?

    Do not stop with one story. Broader context across sectors helps you spot patterns, compare risk profiles, and build a watchlist that really reflects your goals.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.